NEW YORK, Oct. 11 – Xtrana has been issued a US patent for a family of its nucleic acid extraction matrices, the company said on Wednesday.

The patent, numbered 6,291,166 and entitled "Nucleic Acid Archiving,” represents “the foundation technologies” for Xtrana products, according to a company statement.

The matrices, called Xtra Bind, capture and stabilize DNA and RNA and facilitate enzymatic manipulation of the nucleic acid, which Xtrana says results in “an extremely rapid and efficient extraction protocol.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.